RT Journal Article
SR Electronic
T1 Umbilical Cord Blood DNA Methylation in Children Who Later Develop Type 1 Diabetes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.21.21257593
DO 10.1101/2021.05.21.21257593
A1 Essi Laajala
A1 Ubaid Ullah
A1 Toni Grönroos
A1 Omid Rasool
A1 Viivi Halla-aho
A1 Mikko Konki
A1 Roosa Kattelus
A1 Juha Mykkänen
A1 Mirja Nurmio
A1 Mari Vähä-Mäkilä
A1 Henna Kallionpää
A1 Niina Lietzén
A1 Bishwa R. Ghimire
A1 Asta Laiho
A1 Heikki Hyöty
A1 Laura L. Elo
A1 Jorma Ilonen
A1 Mikael Knip
A1 Riikka J. Lund
A1 Matej Orešič
A1 Riitta Veijola
A1 Harri Lähdesmäki
A1 Jorma Toppari
A1 Riitta Lahesmaa
YR 2021
UL http://medrxiv.org/content/early/2021/05/25/2021.05.21.21257593.abstract
AB Distinct DNA methylation patterns have recently been observed to precede type 1 diabetes in whole blood collected from young children. Our aim was to determine, whether perinatal DNA methylation could be associated with later progression to type 1 diabetes. Reduced representation bisulfite sequencing (RRBS) analysis was performed on umbilical cord blood samples collected within the Type 1 Diabetes Prediction and Prevention (DIPP) study. Children later diagnosed with type 1 diabetes and/or testing positive for multiple islet autoantibodies (N=43) were compared to control individuals (N=79), who remained autoantibody-negative throughout the DIPP follow-up until 15 years of age. Potential confounding factors related to the pregnancy and the mother were included in the analysis. No differences in the cord blood methylation patterns were observed between these cases and controls.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by InFLAMES Flagship Programme of the Academy of Finland (decision number: 337530). R.V. received funding for the DIPP study from the JDRF (grants 1-SRA-2016-342-M-R and 1-SRA-2019-732-M-B), Academy of Finland (grant 308067) and the Finnish Diabetes Foundation. The DIPP Study was also supported by Special Research Funds for University Hospitals in Finland. R.La. received funding from the Academy of Finland (grants 292335, 294337, 319280, 31444, 319280, 329277, 331790), Business Finland and by grants from the JDRF, the Sigrid Jusélius Foundation (SJF), Jane and Aatos Erkko Foundation, Finnish Diabetes Foundation and the Finnish Cancer Foundation. R.La., H.L., M.K., M.O. and J.T. were supported by the Academy of Finland, AoF, Centre of Excellence in Molecular Systems Immunology and Physiology Research (2012-2017) grant 250114 and grant 292482. J.T. was funded by EFSD, Pediatric Research Foundation, and Turku University Hospital Special Governmental Grants. L.L.E. reports grants from the European Research Council ERC (677943), European Union’s Horizon 2020 research and innovation programme (675395), Academy of Finland (296801, 310561, 314443, 329278, 335434 and 335611), and Sigrid Jusélius Foundation. Our research is also supported by University of Turku Graduate School (UTUGS), Biocenter Finland, and ELIXIR Finland. E.L. was supported by Turku Doctoral Programme of Molecular Medicine (TuDMM), Finnish Cultural Foundation, and Kyllikki and Uolevi Lehikoinen Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was originally approved by the Ethics Committee of the Hospital District of Southwest Finland followed by the Ethics Committee of the Hospital District of Northern Ostrobothnia. The study followed the principals of the Helsinki II declaration.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during the current study will be available in a public repository as soon as the manuscript is accepted for publication in a peer-reviewed journal. The code is available in https://github.com/EssiLaajala/RRBS_workflow, where also the data availability status will be updated.